Theravance Historical Income Statement
| TBPH Stock | USD 9.12 0.02 0.22% |
Historical analysis of Theravance Biopharma income statement accounts such as Other Operating Expenses of 105.2 M, Research Development of 38.6 M, Cost Of Revenue of 5.7 M or Total Operating Expenses of 105.2 M can show how well Theravance Biopharma performed in making a profits. Evaluating Theravance Biopharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Theravance Biopharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Theravance Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Theravance Biopharma is a good buy for the upcoming year.
Theravance |
About Theravance Income Statement Analysis
Theravance Biopharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Theravance Biopharma shareholders. The income statement also shows Theravance investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Theravance Biopharma Income Statement Chart
Theravance Biopharma Income Statement is one of the three primary financial statements used for reporting Theravance's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Theravance Biopharma revenue and expense. Theravance Biopharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of now, Theravance Biopharma's Income Tax Expense is increasing as compared to previous years. The Theravance Biopharma's current Tax Provision is estimated to increase to about 2.5 M, while Depreciation And Amortization is projected to decrease to under 4 M. Add Fundamental
Total Revenue
Total revenue comprises all receipts Theravance Biopharma generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Theravance Biopharma. It is also known as Theravance Biopharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Theravance Biopharma income statement and represents the costs associated with goods and services Theravance Biopharma provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from Theravance Biopharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Theravance Biopharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.As of now, Theravance Biopharma's Income Tax Expense is increasing as compared to previous years. The Theravance Biopharma's current Tax Provision is estimated to increase to about 2.5 M, while Depreciation And Amortization is projected to decrease to under 4 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 293.0M | 130.5M | 110.7M | 105.2M | Cost Of Revenue | 7.3M | 6.6M | 6.1M | 5.7M |
Theravance Biopharma income statement Correlations
Click cells to compare fundamentals
Theravance Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Theravance Biopharma income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 42.1M | 71.3M | 125.2M | 21.4M | 4.3M | 4.0M | |
| Interest Expense | 31.9M | 44.6M | 46.9M | 6.4M | 2.4M | 2.2M | |
| Total Revenue | 73.4M | 71.9M | 55.3M | 51.3M | 57.4M | 56.6M | |
| Gross Profit | (145.8M) | (189.1M) | 48.0M | 44.8M | 51.4M | 53.9M | |
| Other Operating Expenses | 325.3M | 369.6M | 293.0M | 130.5M | 110.7M | 105.2M | |
| Operating Income | (251.9M) | (297.8M) | (257.8M) | (92.0M) | (53.3M) | (56.0M) | |
| Ebit | (251.9M) | (297.8M) | (257.8M) | (92.0M) | (44.5M) | (46.8M) | |
| Research Development | 219.2M | 261.0M | 193.7M | 63.4M | 40.6M | 38.6M | |
| Ebitda | (209.8M) | (226.5M) | (132.5M) | (70.6M) | (40.3M) | (42.3M) | |
| Cost Of Revenue | 219.2M | 261.0M | 7.3M | 6.6M | 6.1M | 5.7M | |
| Total Operating Expenses | 325.3M | 369.6M | 293.0M | 130.5M | 110.7M | 105.2M | |
| Income Before Tax | (241.7M) | (286.5M) | (199.6M) | (92.8M) | (49.3M) | (51.7M) | |
| Net Income | (236.5M) | (278.0M) | (199.4M) | (92.8M) | (55.2M) | (58.0M) | |
| Selling General Administrative | 106.1M | 108.7M | 99.3M | 59.1M | 65.0M | 91.3M | |
| Net Income From Continuing Ops | (236.5M) | (278.0M) | (199.4M) | (92.8M) | (60.9M) | (64.0M) | |
| Total Other Income Expense Net | 10.2M | 11.2M | 58.2M | (858K) | 4.0M | 3.8M | |
| Net Income Applicable To Common Shares | (236.5M) | (278.0M) | (199.4M) | 872.1M | 1.0B | 1.1B | |
| Income Tax Expense | (5.2M) | (8.5M) | (151K) | 9K | 5.9M | 6.2M | |
| Non Operating Income Net Other | 42.1M | 55.8M | 105.1M | 5.5M | 6.3M | 6.0M | |
| Tax Provision | (5.2M) | (8.5M) | (151K) | 9K | 2.4M | 2.5M | |
| Interest Income | 8.4M | 2.8M | 1.1M | 8.5M | 11.0M | 6.2M | |
| Net Interest Income | (23.5M) | (41.8M) | (45.8M) | 2.2M | 8.7M | 9.1M | |
| Reconciled Depreciation | 6.2M | 9.1M | 9.7M | 7.0M | 4.9M | 6.9M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Theravance Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Theravance Biopharma's short interest history, or implied volatility extrapolated from Theravance Biopharma options trading.
Currently Active Assets on Macroaxis
When determining whether Theravance Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Theravance Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Theravance Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Theravance Biopharma Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Theravance Stock analysis
When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Theravance Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.00) | Revenue Per Share 1.038 | Quarterly Revenue Growth 0.199 | Return On Assets (0.07) | Return On Equity (0.17) |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.